Swiss approval for Zevtera in treatment of complicated skin and soft tissue infections
The National Institutes of Health (NIH) has awarded nearly $3 million to support Rush University Medical Center’s study analyzing how human breast milk impacts the health outcomes and health care cost savings for very low birth weight infants - babies less than 1500 grams. The grant will enable researchers at Rush to conduct a five-year study
Full Post: Study to examine how breastfeeding impacts cost of healthcare for very low birth weight babies
Swissmedic, the Swiss agency for therapeutic products, has approved Zevtera (ceftobiprole medocaril) for the treatment of complicated skin and soft tissue infections, including diabetic foot infections which have not spread to the bone.
Ceftobiprole is licensed from and co-developed with Basilea Pharmaceutica Ltd. Janssen-Cilag will market ceftobiprole in Switzerland under the trade name Zevtera. Swiss based Basilea Pharmaceutica Ltd will co-promote the drug in key European markets and North America.
Ceftobiprole is the first, broad-spectrum, anti-MRSA cephalosporin antibiotic with activity against a range of difficult-to-treat Gram-positive and Gram-negative hospital- and community-acquired pathogens including methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. In clinical trials, ceftobiprole has demonstrated high cure rates in patients with complicated skin infections, including those caused by the potentially deadly MRSA.
Data from the European Antimicrobial Resistance Surveillance System (EARSS) show that the prevalence of MRSA - a difficult to treat cause of hospital-and- community acquired infections - while varying considerably among countries, has been rising across Europe for the past six years.
The use of ceftobiprole in adults for the treatment of complicated soft tissue infections, including diabetic foot infections which have not spread to the bone, is under regulatory review in United States, Australia and in the European Union among other countries. In Canada, ceftobiprole was launched in August 2008 under the trade name Zevtera.
Complicated skin and soft tissue infections are among the most common infections in the hospital setting. Staphylococcus aureus is the predominant pathogen in these infections. In recent years, resistant strains, such as MRSA have become increasingly common and have been associated with increased morbidity and mortality. New broad-spectrum antibiotics that cover resistant bacteria such as MRSA, but also clinically important and problematic Gram-negative pathogens, address a high-unmet medical need in the treatment of severe skin and soft tissue infections.
Patients with chronic wounds or those who have recently received antibiotics may also be infected by Gram-negative pathogens. This is frequently the case for diabetic patients with foot infections. Adequate treatment of diabetic foot infections can require hospitalization, surgery and broad-spectrum intravenous antibiotics.
Ceftobiprole, the first anti-MRSA cephalosporin to be approved, is an intravenous antibiotic that belongs to the class of antibacterial drugs known as cephalosporins, which are used to treat serious infections caused by a broad range of bacteria, characterized as Gram-negative and Gram-positive, based on a classification process that is used to identify the specific type of bacteria.
Phase III clinical trials have demonstrated that ceftobiprole is clinically efficacious against the following pathogens: Enterobacter cloacae, Enterococcus faecalis, Proteus mirabilis, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus agalactiae, Streptococcus pyogenes, Escherichia coli, Klebsiella pneumonia and Pseudomonas aeruginosa.
The Janssen-Cilag company have a long and successful track record in developing and marketing treatments for a wide variety of conditions such as infectious disease, HIV, pain management, fungal infections, multiple myeloma, gastroenterological disorders, epilepsy, Alzheimer’s disease, schizophrenia, acute bipolar mania, behavioural psychological symptoms of dementia, disruptive behaviour disorders, and autism.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), has announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ceftobiprole for the treatment of complicated skin and skin structure infections, including diabetic foot infections. The FDA has indicated that they cannot approve
Full Post: FDA issues complete response letter for Ceftobiprole for treatment of complicated skin infections
Targanta Therapeutics Corporation announced today that the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the November 19, 2008 Anti-Infective Drugs Advisory Committee (AIDAC) meeting. AIDAC will review Targanta’s New Drug Application (NDA) for oritavancin for the treatment of complicated skin and skin structure infection (cSSSI) caused by gram-positive
Full Post: Targanta Therapeutics announces posting of briefing documents for review of FDA
Pre-operative screening of patients for methicillin-resistant Staphylococcus aureus (MRSA) may be an effective way to reduce infection rates following otolaryngic surgeries, according to new research published in the January 2009 issue of Otolaryngology - Head and Neck Surgery. The study, conducted by researchers at the Massachusetts Ear & Eye Infirmary, is the first to review otolaryngic
Full Post: MRSA pre-screening effective in reducing otolaryngic surgical infection rates
Infectious disease experts warn that new drugs are urgently needed to treat six drug-resistant bacteria that cause most hospital infections and increasingly escape the effects of antibiotics. The ESKAPE pathogens - as these six bad bugs have been dubbed - are still on the loose more than four years after the Infectious Diseases Society of
Full Post: Six bad bugs increasingly escaping effects of antibiotics
Two clones of highly antibiotic-resistant organism strains, which previously had only been identified in the United States, are now causing serious sickness and death in several Colombian cities including the capital Bogota, say researchers at The University of Texas Medical School at Houston. The study, done in collaboration with Universidad El Bosque in Bogotá, is
Full Post: U.S. ’super bugs’ invading several Colombian cities